Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ORCA Therapeutics BV

Latest From ORCA Therapeutics BV

Venture Funding Deals, May 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2016.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • ORCA Therapeutics BV
  • Senior Management
  • Kees Groen, PhD, CEO
    Ir. Jan van der Hoeven, CFO
    Victor van Beusechem, PhD, CSO
    Wenliang Dong, PhD, COO
  • Contact Info
  • ORCA Therapeutics BV
    Phone: 24 3529 805
    Jonkerbosplein 52
    Nijmegen, 6534 AB